Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

'Increased statin doses cut heart attack rates'

  • 1 Comment

The number of heart attacks and strokes could be reduced if patients took stronger doses of cholesterol-lowering drugs, a new study has shown.

Researchers from the UK and Australia investigated whether more potent doses of statins had an effect on death and heart attack rates.

Statins are among the world’s biggest-selling drugs and are taken by millions of people each year. They work by blocking the action of an enzyme in the liver which is needed to make cholesterol.

The findings showed that there was a “highly significant” (15%) reduction in major heart attacks and strokes when stronger treatments were taken.

Heart-related deaths or non-fatal heart attacks were cut by 13%, the number of patients that required a bypass or other coronary treatments dropped by 19%, and strokes reduced by 16%.

Nearly 40,000 high-risk patients were part of the research, which measured effects after one year of taking either regular or intensive statin treatment to combat LDL cholesterol.

Lead researcher Colin Baigent, of Oxford University, said: “It is a continuous relationship, right the way down to very low levels of LDL cholesterol.”

The research found no significant effects on deaths due to cancer or other non-vascular causes.

But it warned that simply raising the dose of the most commonly used statin in the UK - simvastatin, might lead to some health problems.

A rare side-effect of simvastatin is muscle weakness, known as myopathy, and in some cases it can lead to more serious muscle damage.

“Guidelines have proposed that high doses of generic statins be used to achieve these benefits, but such regimens may be associated with higher risk of myopathy,” the study said.

“Instead, these benefits may be achieved more safely with newer, more potent statins.”

The British Heart Foundation, which part-funded the study, backed the study.

  • 1 Comment

Readers' comments (1)

  • Hmm, interesting to note the research was funded by Merck who also happen to produce simvastatin. How to assess the impact of (albeit voluntarily disclosed) vested interests?

    Unsuitable or offensive? Report this comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs